Comparative Pharmacology
Head-to-head clinical analysis: ECOZA versus PENLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECOZA versus PENLAC.
ECOZA vs PENLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Ciclopirox, a hydroxypyridone antifungal, inhibits the uptake of essential elements and disrupts fungal cell membrane integrity by chelating polyvalent cations (Fe3+, Al3+). It also inhibits fungal enzymes involved in energy production and detoxification processes.
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
Apply a thin layer to affected nails once daily, preferably at bedtime or 8 hours before washing. Use the provided applicator to apply to the entire nail plate and under the nail tip. Treatment duration is up to 48 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal elimination half-life is 17–21 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe renal failure)
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Primarily excreted renally as unchanged drug; approximately 90% of absorbed dose recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%)
Category C
Category C
Topical Antifungal
Topical Antifungal